Zoster‑induced conjunctivitis - Causes, Treatment & When to See a Doctor

What is Zoster‑induced conjunctivitis?

Zoster‑induced conjunctivitis is inflammation of the conjunctiva—the thin, transparent membrane that lines the inside of the eyelids and covers the white part of the eye (the sclera)—that occurs after infection with the varicella‑zoster virus (VZV). VZV is the same virus that causes chickenpox (varicella) and shingles (herpes zoster). When the virus reactivates in the trigeminal (cranial) nerve, it can spread to the eye and cause a spectrum of ocular problems, collectively called “herpes zoster ophthalmicus” (HZO). Conjunctivitis is often the earliest visible sign of HZO, but it can progress to more serious complications such as keratitis, uveitis, or even vision loss if not promptly treated.

According to the CDC and the Mayo Clinic, the risk of HZO increases with age, immunosuppression, and a history of chickenpox. The conjunctival inflammation typically appears as redness, tearing, and a gritty sensation, and may be accompanied by a vesicular rash on the eyelid or forehead.

Common Causes

While VZV reactivation is the direct cause, several underlying factors predispose a person to develop zoster‑induced conjunctivitis:

• Reactivation of varicella‑zoster virus in the ophthalmic branch of the trigeminal nerve.
• Advanced age (risk rises sharply after age 50).
• Immunosuppression – HIV infection, organ transplantation, chemotherapy, long‑term steroids.
• Chronic systemic diseases – diabetes mellitus, chronic kidney disease, or malignancy.
• Previous shingles episode involving the facial region.
• Stress or physical trauma that can trigger viral reactivation.
• Use of biologic agents such as TNF‑α inhibitors.
• Low cellular immunity due to aging (immunosenescence).
• Vaccination status – lack of shingles vaccination (Shingrix) increases risk.
• Concurrent ocular disease – dry eye, blepharitis, or previous ocular surgery may ease viral spread.

Associated Symptoms

Conjunctivitis rarely occurs in isolation when caused by VZV. Patients often notice a constellation of ocular and facial signs, including:

• Redness of the eye – diffuse hyperemia of the conjunctiva.
• Watery or mucous discharge – may be more pronounced than in bacterial conjunctivitis.
• Gritty or burning sensation – feeling like sand in the eye.
• Photophobia – increased sensitivity to light.
• Periorbital rash – groups of vesicles on the eyelid, forehead, or tip of the nose (Hutchinson’s sign).
• Eyelid edema – swelling that can impede blinking.
• Reduced visual acuity – blurring that may worsen if the cornea becomes involved.
• Headache or facial pain – due to trigeminal nerve involvement.
• Fever or malaise – especially in immunocompromised patients.

When to See a Doctor

Because ocular herpes zoster can rapidly damage the eye, early evaluation is essential. Seek professional care if you notice any of the following:

• Redness or pain in one eye that does not improve within 24‑48 hours.
• Appearance of a vesicular rash on the eyelid, forehead, or bridge of the nose.
• Sudden decrease in vision, double vision, or persistent blurry vision.
• Severe eye pain that feels “deep” or “boring,” especially with a headache.
• Photophobia that interferes with daily activities.
• Swelling of the eyelid that prevents the eye from opening fully.
• Any ocular symptoms in an immunocompromised individual (e.g., transplant recipient, chemotherapy patient).

Prompt ophthalmologic assessment can prevent complications such as corneal ulceration, glaucoma, or permanent vision loss.

Diagnosis

Diagnosis combines a detailed history, a thorough eye examination, and sometimes laboratory testing:

Clinical Evaluation

• History taking: recent shingles, vaccination status, immunosuppressive conditions.
• Slit‑lamp examination: magnified view of the conjunctiva, cornea, and anterior chamber for vesicles, epithelial defects, or stromal haze.
• Fluorescein staining: highlights corneal abrasions or ulcerations that may coexist.
• Assessment of Hutchinson’s sign: lesions on the tip of the nose indicate a high risk of ocular involvement.

Laboratory Tests (when needed)

• Polymerase chain reaction (PCR) of conjunctival swab – highly sensitive for VZV DNA.
• Viral culture – less commonly used due to slower turnaround.
• Serology – may help differentiate primary infection from reactivation, but not routinely required.

Differential Diagnosis

Conditions that can mimic zoster‑induced conjunctivitis include bacterial conjunctivitis, allergic conjunctivitis, adenoviral epidemic keratoconjunctivitis, and contact‑lens‑related keratitis. Distinguishing features are the characteristic vesicular rash and the pattern of nerve distribution.

Treatment Options

Management aims to eradicate the virus, control inflammation, and protect the ocular surface.

Antiviral Therapy

• Acyclovir 800 mg orally five times daily for 7‑10 days is the traditional regimen.
• Valacyclovir 1 g orally three times daily or 2 g twice daily (shorter course) – preferred for better bioavailability.
• Famciclovir 500 mg orally three times daily.
• Intravenous acyclovir is reserved for severe cases, immunocompromised patients, or when oral absorption is doubtful.

Antivirals are most effective when started within 72 hours of rash onset, but treatment is still recommended even later because it can reduce the risk of ocular sequelae.

Topical Therapy

• Topical corticosteroids (e.g., prednisolone acetate 1%) – reduce conjunctival inflammation but must be used under ophthalmologist supervision to avoid exacerbating viral replication.
• Topical antiviral ointments – e.g., trifluridine 1 % (used less frequently due to toxicity). The current standard favors systemic antivirals.
• Lubricating eye drops (preservative‑free artificial tears) – relieve surface irritation and support healing.
• Cycloplegic agents (e.g., homatropine) – relieve ciliary spasm and photophobia if uveitis develops.

Adjunctive Measures

• Cold compresses to the eyelid for comfort.
• Avoid rubbing the eye; use clean hands.
• Discontinue contact lens wear until the eye is clear.
• In immunocompromised patients, consider prophylactic antiviral therapy for up to 6 weeks after the acute episode.

Follow‑up Care

Repeat slit‑lamp examinations are typically scheduled at 48‑hour intervals during the acute phase, then weekly until the conjunctiva and cornea are stable. Persistent corneal involvement may require referral to a cornea specialist.

Prevention Tips

• Shingles vaccination – The recombinant zoster vaccine (Shingrix) is >90 % effective in preventing HZO in adults ≥50 years. CDC recommends it even for those previously vaccinated with the live vaccine.
• Maintain good immunity – balanced diet, regular exercise, adequate sleep, and control of chronic diseases (diabetes, hypertension).
• Hand hygiene – reduces spread of VZV to vulnerable contacts.
• Avoid exposure to individuals with active chickenpox or shingles if you are immunocompromised.
• Prompt treatment of early shingles – initiating antivirals within 72 hours can prevent ophthalmic involvement.
• Protect eyes during outbreaks – wear protective goggles if you develop facial shingles to limit viral contact with the ocular surface.

Emergency Warning Signs